Enrique Pelayo
Internal Medicine · Miami, FLNPI 1932135100
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Amarin Pharma, Inc. at 33.5% of the total. Reporting peaked in 2019 at $194 and has fallen 53.6% since, to $90 in 2025.
Across 25 payments — averaging $29.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$245
- Lilly USA, LLC$149
- Merck$140
- Revance Therapeutics, Inc.$96
- Bayer$49
- GSK$29
- plus $24 from 1 others
Across 691 payments — averaging $7768.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.9M
- GSK$1.2M
- Acella Pharmaceuticals, LLC$341K
- Astrazeneca UK Limited$243K
- Ionis Pharmaceuticals, Inc.$232K
- AbbVie$226K
- plus $260K from 6 others
What the payments were for
- Food & beverage$72699%
- Education$61%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 7 | $245 |
| Lilly USA, LLC | 8 | $149 |
| Merck | 4 | $140 |
| Revance Therapeutics, Inc. | 2 | $96 |
| Bayer | 2 | $49 |
| GSK | 1 | $29 |
| Novo Nordisk | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$134
How this compares
$731 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 46 | $45,851 |
| JardianceEmpagliflozin | 35 | $37,410 |
| OzempicSemaglutide | 26 | $27,012 |
| EliquisApixaban | 23 | $17,091 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $14,022 |
| TrulicityDulaglutide | 12 | $11,845 |
| VascepaIcosapent Ethyl | 28 | $10,468 |
| Omega-3 Acid Ethyl Esters | 35 | $3,226 |
| Omeprazole | 168 | $2,512 |
| Atorvastatin Calcium | 344 | $1,664 |
| LantusInsulin Glargine,hum.Rec.Anlog | 21 | $1,315 |
| Famotidine | 89 | $1,229 |
| Gabapentin | 80 | $1,148 |
| Insulin Aspart | 15 | $1,055 |
| Losartan Potassium | 230 | $950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $140 | $59,87368 claims |
| Novo NordiskOzempic | $24 | $27,01226 claims |
| Lilly USA, LLCTrulicity | $149 | $11,84512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami
- Haytham ElgammalMiami$2.2M
- Richard AguilarMiami$239K
- Maria Delgado LelievreMiami$80K
- Marlow HernandezMiami$58K
- Steven CohnMiami$47K
- Joseph PiperatoMiami$45K
- Simon AbelsonMiami$44K
- Joel Brooks TamayoMiami$42K
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.